Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy

CAFC
  • US 5,552,394 A
  • Filed: 07/22/1994
  • Issued: 09/03/1996
  • Est. Priority Date: 07/22/1994
  • Status: Expired due to Term
First Claim
Patent Images

1. A method of female contraception which is characterized by a reduced incidence of breakthrough bleeding after the first cycle which comprises monophasicly administering a combination of estrogen and progestin for 23-25 consecutive days of a 28 day cycle in which the daily amounts of estrogen and progestin are equivalent to about 1-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively, and in which the weight ratio of estrogen to progestin is at least 1:

  • 45 calculated as ethinyl estradiol to norethindrone acetate.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×